Holen Sie sich die Stockscreener-App
324.09
0.43%
-1.41
Schlusskurs vom Vortag:
$325.50
Offen:
$325.81
24-Stunden-Volumen:
200.57K
Relative Volume:
1.01
Marktkapitalisierung:
$8.74B
Einnahmen:
$2.58B
Nettoeinkommen (Verlust:
$-778.69M
KGV:
-11.86
EPS:
-27.33
Netto-Cashflow:
$223.75M
1W Leistung:
+6.96%
1M Leistung:
+2.01%
6M Leistung:
+31.18%
1J Leistung:
-5.79%
1-Tages-Spanne:
$320.22
$326.90
1-Wochen-Bereich:
$300.42
$328.25
52-Wochen-Spanne:
$211.43
$373.69
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Firmenname
Bio Rad Laboratories Inc
Sektor
Branche
Telefon
(510) 724-7000
Adresse
1000 ALFRED NOBEL DRIVE, HERCULES
Vergleichen Sie BIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
324.09 | 8.78B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
127.04 | 222.19B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.65 | 144.97B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.75 | 140.12B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.77 | 128.60B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.83 | 49.82B | 5.88B | 1.34B | 799.60M | 2.3489 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-06-16 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-01-28 | Bestätigt | Citigroup | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2018-10-17 | Eingeleitet | Goldman | Buy |
| 2018-09-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Herabstufung | CL King | Buy → Neutral |
| 2017-07-13 | Eingeleitet | Wells Fargo | Outperform |
| 2017-06-28 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Hold |
| 2016-10-13 | Eingeleitet | CL King | Buy |
| 2015-05-06 | Bestätigt | Jefferies | Buy |
| 2009-12-18 | Eingeleitet | Maxim Group | Buy |
| 2009-11-06 | Eingeleitet | Jefferies & Co | Buy |
| 2009-07-17 | Eingeleitet | Soleil | Buy |
| 2007-09-26 | Eingeleitet | Banc of America Sec | Buy |
| 2007-02-23 | Herabstufung | Robert W. Baird | Outperform → Neutral |
Alle ansehen
Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten
$43.36 Bn Autism Spectrum Disorder Diagnostics Global Market Trends, Opportunities and Strategies, 2019-2024, 2025-2029F, 2034F - GlobeNewswire Inc.
Laboratory Supplies Market 2026 Forecast: In-Depth Industry - openPR.com
Is Bio Rad Laboratories Inc. stock resilient to inflation2026 world cup usa national team third place match key players high defensive line knockout prediction expert opinion - ulpravda.ru
Basic Statistics in Laboratory Quality Control - Labroots
Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference - BioSpace
United States In-vitro Cancer Diagnostics Market 2025 | Lead - openPR.com
Is Bio Rad Laboratories Inc. Class B stock worth buying before Fed action2026 world cup usa national team round of 16 key players pressing system group prediction insights - ulpravda.ru
Earnings Risk: Can Bio Rad Laboratories Inc stock beat market expectations this quarterJuly 2025 Big Picture & Expert Approved Momentum Trade Ideas - moha.gov.vn
Bio-Rad Laboratories, Inc. $BIO Shares Acquired by Allspring Global Investments Holdings LLC - MarketBeat
Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Helicobacter Pylori Diagnostics Market Forecast Through - openPR.com
Sample Preparation Market 2025 Forecast: In-Depth Industry - openPR.com
Boston Trust Walden Corp Invests $26.76 Million in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Responsive Playbooks and the BIO Inflection - Stock Traders Daily
Marathon Asset Management Ltd Sells 7,893 Shares of Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Protein A Resin Market is expected to reach US$ 4.1 billion by 2032 - openPR.com
Newborn Screening Market Assessment 2032: Segment Analysis, - openPR.com
Japan's Life Sciences Research and Clinical Applications Fuel - openPR.com
BIO (Bio-Rad Laboratories) Sale Of Property, Plant, Equipme - GuruFocus
Harbor Capital Advisors Inc. Lowers Stock Holdings in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
United states DNA Forensics Market to Reach USD 5.60 Billion - openPR.com
United states IVD Quality Control Market expected to grow at - openPR.com
United states Molecular Quality Controls Market expected - openPR.com
Bio-Rad Laboratories Earnings Notes - Trefis
Robust Growth in Molecular Quality Control Market (2025-2032): - openPR.com
Exchange Traded Concepts LLC Buys 7,648 Shares of Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Life Science Instruments & Consumables Market to Reach USD - openPR.com
Enzyme-Linked Immunosorbent Assay Market is expected to reach - openPR.com
BIO (Bio-Rad Laboratories) EV-to-OCF : 16.80 (As of Dec. 23, 2025) - GuruFocus
Bio-Rad Laboratories, Inc. Class A Common Stock (NY: BIO - FinancialContent
Cell Viability Assays Market Soars as Drug Discovery Demand - openPR.com
Why Bio Rad Laboratories Inc. stock attracts global investorsTrade Risk Assessment & Capital Protection Trading Alerts - Улправда
Published on: 2025-12-20 23:30:31 - Улправда
Can Bio Rad Laboratories Inc. (BUW) stock sustain margin levelsJuly 2025 PostEarnings & Risk Managed Trade Strategies - bolumsonucanavari.com
How Bio Rad Laboratories Inc. stock performs in interest rate cycles2025 Top Decliners & Capital Efficient Trading Techniques - Улправда
Published on: 2025-12-20 08:31:22 - Улправда
Will Bio Rad Laboratories Inc. stock recover faster than marketMarket Sentiment Review & Safe Entry Point Identification - Улправда
Why Bio Rad Laboratories Inc. stock is trending among retail tradersJuly 2025 Snapshot & Capital Efficient Trade Techniques - Bölüm Sonu Canavarı
Why Bio Rad Laboratories Inc. stock is rated strong buy2025 Biggest Moves & Weekly Return Optimization Plans - ulpravda.ru
Why Bio Rad Laboratories Inc. (BUW) stock is a must watch tickerMarket Sentiment Report & Real-Time Buy Zone Alerts - DonanımHaber
Is Bio Rad Laboratories Inc. stock a smart buy before Fed meetingJuly 2025 Retail & Entry Point Confirmation Alerts - DonanımHaber
Published on: 2025-12-19 13:52:52 - DonanımHaber
Is Bio Rad Laboratories Inc. stock in correction or buying zone2025 Performance Recap & Low Drawdown Momentum Trade Ideas - DonanımHaber
Liquidity Mapping Around (BIO) Price Events - Stock Traders Daily
Loss Report: Is Bio Rad Laboratories Inc. Class B stock worth buying before Fed action - Улправда
Guidance Update: Will Bio Rad Laboratories Inc. stock gain from government policies2025 Fundamental Recap & AI Powered Buy and Sell Recommendations - Улправда
Bio-Rad Laboratories (FRA:BUWA) EV-to-FCF : 22.87 (As of Dec. 18, 2025) - GuruFocus
Assessment of InteliQ Multiqual Tube-Based QC Materials - Labroots
Bio-Rad Fails in Bid to Exclude Internal Communications in Ex-GC's Whistleblower Suit - Law.com
In Vitro Toxicity Testing Market Set for Dynamic Growth with Key - openPR.com
Published on: 2025-12-18 13:31:33 - Улправда
Finanzdaten der Bio Rad Laboratories Inc-Aktie (BIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.64%
0.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):